

National Institute for
Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BD

20th August 2010

Dear Raphael

Regarding: Appraisal Consultation Document; Prucalopride for the treatment of chronic constipation in women

On behalf of Movetis, I would like to thank the NICE appraisal committee for their preliminary recommendation regarding the use of prucalopride and the treatment of women with chronic constipation.

Movetis concurs with the committee and their conclusion that prucalopride should only be considered in women who have been managed by a clinician with experience of treating chronic constipation. The women should have tried at least two different types of laxative, and lifestyle modification, for at least 6 months, but have not had relief from constipation.

The consultation document raises a number of questions; I have addressed and commented on these questions in the attached document. I would be grateful for your consideration of this document in response to the appraisal committee's preliminary decision.

If you require any further information please contact me directly: mobile phone [REDACTED], email [REDACTED].

Yours sincerely

[REDACTED] Movetis UK